Consensus summary of aerosolized antimicrobial agents: application of guideline criteria. Insights from the Society of Infectious Diseases Pharmacists.

Published

Journal Article

Aerosolized delivery of antimicrobial agents is an attractive option for management of pulmonary infections, as this is an ideal method of providing high local drug concentrations while minimizing systemic exposure. With the paucity of consensus regarding the safety, efficacy, and means with which to use aerosolized antimicrobials, a task force was created by the Society of Infectious Diseases Pharmacists to critically review and evaluate the literature on the use of aerosolized antiinfective agents. This article summarizes key findings and statements for preventing or treating a variety of infectious diseases, including cystic fibrosis, bronchiecstasis, hospital-acquired pneumonia, fungal infections, nontuberculosis mycobacterial infection, and Pneumocystis jiroveci pneumonia. Our intention was to provide guidance for clinicians on the use of aerosolized antibiotics through evidence-based pharmacotherapy. Further research with well-designed clinical trials is necessary to elucidate the optimal dosage and duration of therapy and, of equal importance, to appreciate the true risks associated with the use of aerosolized delivery systems.

Full Text

Duke Authors

Cited Authors

  • Le, J; Ashley, ED; Neuhauser, MM; Brown, J; Gentry, C; Klepser, ME; Marr, AM; Schiller, D; Schwiesow, JN; Tice, S; VandenBussche, HL; Wood, GC; Society of Infectious Diseases Pharmacists Aerosolized Antimicrobials Task Force,

Published Date

  • June 2010

Published In

Volume / Issue

  • 30 / 6

Start / End Page

  • 562 - 584

PubMed ID

  • 20500046

Pubmed Central ID

  • 20500046

Electronic International Standard Serial Number (EISSN)

  • 1875-9114

Digital Object Identifier (DOI)

  • 10.1592/phco.30.6.562

Language

  • eng

Conference Location

  • United States